Ilyas Åahin

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8172502/publications.pdf

Version: 2024-02-01

53	1,139	566801 15	414034 32
papers	citations	h-index	g-index

56	56	56	2152
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	C1013G/CXCR4 acts as a driver mutation of tumor progression and modulator of drug resistance in lymphoplasmacytic lymphoma. Blood, 2014, 123, 4120-4131.	0.6	187
2	CXCR4 Regulates Extra-Medullary Myeloma through Epithelial-Mesenchymal-Transition-like Transcriptional Activation. Cell Reports, 2015, 12, 622-635.	2.9	123
3	The sialyltransferase ST3GAL6 influences homing and survival in multiple myeloma. Blood, 2014, 124, 1765-1776.	0.6	97
4	Role of endothelial progenitor cells in cancer progression. Biochimica Et Biophysica Acta: Reviews on Cancer, 2014, 1846, 26-39.	3.3	70
5	Drug Delivery Approaches for the Treatment of Cervical Cancer. Pharmaceutics, 2016, 8, 23.	2.0	65
6	Glycogen synthase kinase-3 beta inhibitors as novel cancer treatments and modulators of antitumor immune responses. Cancer Biology and Therapy, 2019, 20, 1047-1056.	1.5	59
7	Pyk2 promotes tumor progression in multiple myeloma. Blood, 2014, 124, 2675-2686.	0.6	51
8	Mogamulizumab: a new tool for management of cutaneous T-cell lymphoma . OncoTargets and Therapy, 2019, Volume 12, 1085-1094.	1.0	48
9	Targeting vasculogenesis to prevent progression in multiple myeloma. Leukemia, 2016, 30, 1103-1115.	3.3	46
10	Soy Isoflavones in Integrative Oncology: Increased Efficacy and Decreased Toxicity of Cancer Therapy. Integrative Cancer Therapies, 2019, 18, 153473541983531.	0.8	43
11	AMG-232 sensitizes high MDM2-expressing tumor cells to T-cell-mediated killing. Cell Death Discovery, 2020, 6, 57.	2.0	41
12	CXCR7-dependent angiogenic mononuclear cell trafficking regulates tumor progression in multiple myeloma. Blood, 2014, 124, 1905-1914.	0.6	32
13	Outcomes of locally advanced breast cancer patients with â‰¥10 positive axillary lymph nodes. Medical Oncology, 2013, 30, 615.	1.2	22
14	MEK inhibitors reduce cellular expression of ACE2, pERK, pRb while stimulating NK-mediated cytotoxicity and attenuating inflammatory cytokines relevant to SARS-CoV-2 infection. Oncotarget, 2020, 11, 4201-4223.	0.8	22
15	The Role of Immune Checkpoint Blockade in the Hepatocellular Carcinoma: A Review of Clinical Trials. Frontiers in Oncology, 2021, 11, 801379.	1.3	21
16	Detection of clonotypic DNA in the cerebrospinal fluid as a marker ofÂcentral nervous system invasion in lymphoma. Blood Advances, 2021, 5, 5525-5535.	2.5	18
17	The influence of hypoxia on CML trafficking through modulation of CXCR4 and E-cadherin expression. Leukemia, 2013, 27, 961-964.	3.3	17
18	Clonal haematopoiesis of indeterminate potential among cancer survivors exposed to myelotoxic chemotherapy. British Journal of Haematology, 2019, 186, e31-e35.	1.2	17

#	Article	IF	Citations
19	WaldenstrÃ¶m macroglobulinemia: from biology to treatment. Expert Review of Hematology, 2014, 7, 157-168.	1.0	16
20	Citron Rho-interacting kinase silencing causes cytokinesis failure and reduces tumor growth in multiple myeloma. Blood Advances, 2019, 3, 995-1002.	2.5	15
21	Targeting survival and cell trafficking in multiple myeloma and <scp>W</scp>aldenstrom macroglobulinemia using panâ€class <scp>I PI</scp>3<scp>K</scp> inhibitor, buparlisib. American Journal of Hematology, 2014, 89, 1030-1036.	2.0	14
22	Therapeutic Targeting of Alternative RNA Splicing in Gastrointestinal Malignancies and Other Cancers. International Journal of Molecular Sciences, 2021, 22, 11790.	1.8	13
23	Distinct roles of class I PI3K isoforms in multiple myeloma cell survival and dissemination. Blood Cancer Journal, 2014, 4, e204-e204.	2.8	11
24	Management of polyorchidism: Surgery or conservative management?. Journal of Human Reproductive Sciences, 2010, 3, 162.	0.4	9
25	Strategies to sensitize cancer cells to immunotherapy. Human Vaccines and Immunotherapeutics, 2021, 17, 2595-2601.	1.4	9
26	Androgen receptor-independent prostate cancer: an emerging clinical entity. Cancer Biology and Therapy, 2018, 19, 347-348.	1.5	7
27	Refractoriness to red blood cell transfusion therapy due to hypersplenism. Transfusion, 2018, 58, 2513-2516.	0.8	6
28	A pilot study of 3D tissue-engineered bone marrow culture as a tool to predict patient response to therapy in multiple myeloma. Scientific Reports, 2021, 11, 19343.	1.6	6
29	3D tissue engineered plasma cultures support leukemic proliferation and induces drug resistance. Leukemia and Lymphoma, 2021, 62, 1-9.	0.6	5
30	Cerebrospinal Fluid (CSF) Analysis of Tumor-Specific Cell-Free DNA (cfDNA) As a Diagnostic and Prognostic Tool for Central Nervous System (CNS) Invasion in Lymphoma. Blood, 2020, 136, 21-22.	0.6	5
31	Aspirin intake may prevent metastasis in patients with triple-negative breast cancer. Medical Oncology, 2011, 28, 1308-1310.	1.2	4
32	Bone Marrow Mobilization Of Endothelial Progenitor Cells Represents An Early Pathogenic Event During Multiple Myeloma Progression. Blood, 2013, 122, 680-680.	0.6	4
33	Erythrophagocytosis on bone marrow found in severe autoimmune hemolytic anemia with reticulocytopenia. Blood, 2019, 134, 1877-1877.	0.6	3
34	Asciminib in Relapsed Chronic Myeloid Leukemia. New England Journal of Medicine, 2020, 382, 1378-1379.	13.9	3
35	Hyperprogression of a mismatch repair-deficient colon cancer in a humanized mouse model following administration of immune checkpoint inhibitor pembrolizumab. Oncotarget, 2021, 12, 2131-2146.	0.8	3
36	Lin28B/Let-7 Axis Regulates Multiple Myeloma Proliferation By Enhancing c-Myc and Ras Survival Pathways. Blood, 2013, 122, 273-273.	0.6	3

#	Article	IF	Citations
37	Possible mechanisms behind taxaneâ€“anthracycline sequencing. Lancet Oncology, The, 2010, 11, 514-515.	5.1	2
38	Mirna Expression Profiling and Proteomic Analysis Of Circulating Exosomes From Multiple Myeloma Patients. Blood, 2013, 122, 3086-3086.	0.6	2
39	A pancancer analysis of impact of MDM2/MDM4 on immune checkpoint blockade (ICB).. Journal of Clinical Oncology, 2022, 40, 2630-2630.	0.8	2
40	How can Nolvadex abolish arthralgia in women taking newer generic Tamoxifen preparations?. Breast, 2010, 19, 436.	0.9	1
41	Mechanisms behind the antiâ€tumour effects of zoledronic acid use in multiple myeloma. British Journal of Haematology, 2010, 151, 530-531.	1.2	1
42	CXCR4 Is a Regulator Of Disease Involvement Of Extramedullary Myeloma Confirmed By a Novel Mouse Model For Extramedullary Disease. Blood, 2013, 122, 5320-5320.	0.6	1
43	Recipients of Myelotoxic Chemotherapy Have Increased Prevalence of Clonal Hematopoiesis of Indeterminate Potential (CHIP) with a Typical Distribution of Chip-Associated Mutations. Blood, 2018, 132, 3841-3841.	0.6	1
44	Sequential taxane and anthracycline-containing neo-adjuvant regimens; any rationale behind the sequence?. Breast, 2011, 20, 291.	0.9	0
45	Metabolomic Profiling Identifies Mechanisms Regulating Hypoxia-Induced Drug Resistance in Multiple Myeloma. Blood, 2012, 120, 3944-3944.	0.6	0
46	Proline-Rich Tyrosine Kinase (Pyk2) Promotes Tumor Progression In Multiple Myeloma Through Modulation Of Wnt/Î²-Catenin Signaling Pathway. Blood, 2013, 122, 3094-3094.	0.6	0
47	Class I PI3K Isoforms Exert a Differential Role On Survival and Cell Trafficking In Multiple Myeloma. Blood, 2013, 122, 3159-3159.	0.6	0
48	Silencing The Sialyltransferase Gene ST3GAL6 Inhibits Adhesion and Migration Of Myeloma Cells In Vitro and Reduces The Homing and Proliferation Of Tumor Cells In Vivo. Blood, 2013, 122, 275-275.	0.6	0
49	Citron Rho-Interacting Serine/Threonine kinase (CIT) Is a Novel Therapeutic Target in Multiple Myeloma Cells. Blood, 2014, 124, 3430-3430.	0.6	0
50	Early Trafficking of Bone Marrow Derived-Endothelial Progenitor Cells Promotes Multiple Myeloma Progression. Blood, 2014, 124, 4719-4719.	0.6	0
51	Proline-Rich Tyrosine Kinase (Pyk2) Promotes Tumor Progression in Multiple Myeloma (MM) and Represents a Novel Target for Therapy in MM. Blood, 2014, 124, 2101-2101.	0.6	0
52	3D Tissue-Engineered Bone Marrow Culture Predicts Patient Response to Drugs in Multiple Myeloma. Blood, 2021, 138, 2690-2690.	0.6	0
53	Impact of metastasectomy for extrahepatic disease in stage IV colon cancer: A retrospective cohort NCDB analysis.. Journal of Clinical Oncology, 2022, 40, e15548-e15548.	0.8	0